FDA Okays At-Home Starting Dose for Lecanemab

The FDA has made a significant change by approving the first at-home starting dose for lecanemab, a treatment for Alzheimer's disease. This move is a big deal because it allows patients or their caregivers to begin treatment at home, potentially increasing accessibility and reducing the burden on healthcare facilities. The approval highlights the importance of making treatments for chronic conditions like Alzheimer's more convenient and patient-centered, potentially improving compliance and overall outcomes. This step forward reflects the evolving landscape of Alzheimer's care and the ongoing efforts to address its challenges.